Reply to "Oral Formulation and SGLT2i Interaction: Key Nuances in Semaglutide's Effect on Atrial Fibrillation".

IF 8.4 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European journal of preventive cardiology Pub Date : 2025-05-19 DOI:10.1093/eurjpc/zwaf298

Arturo Cesaro, Vincenzo Acerbo, Paolo Calabrò

引用次数: 0

查看原文本刊更多论文

回复“口服制剂和SGLT2i相互作用：西马鲁肽治疗心房颤动的关键细微差别”。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European journal of preventive cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

12.50

自引率

12.00%

发文量

601

审稿时长

3-8 weeks

期刊介绍： European Journal of Preventive Cardiology (EJPC) is an official journal of the European Society of Cardiology (ESC) and the European Association of Preventive Cardiology (EAPC). The journal covers a wide range of scientific, clinical, and public health disciplines related to cardiovascular disease prevention, risk factor management, cardiovascular rehabilitation, population science and public health, and exercise physiology. The categories covered by the journal include classical risk factors and treatment, lifestyle risk factors, non-modifiable cardiovascular risk factors, cardiovascular conditions, concomitant pathological conditions, sport cardiology, diagnostic tests, care settings, epidemiology, pharmacology and pharmacotherapy, machine learning, and artificial intelligence.